NovoCure Ltd [NVCR] stock is trading at $19.26, up 0.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVCR shares have gain 0.16% over the last week, with a monthly amount drifted -18.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on December 02, 2024, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $30 from $18. Previously, H.C. Wainwright upgraded its rating to Buy on October 16, 2024, and elevated its price target to $30. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to a Overweight but $45 remained the price target by the analyst firm on August 08, 2023. SVB Securities started tracking with a Outperform rating for this stock on August 04, 2023, and assigned it a price target of $51. In a note dated July 31, 2023, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $33.
NovoCure Ltd [NVCR] stock has fluctuated between $11.70 and $34.13 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $19.26 at the most recent close of the market. An investor can expect a potential return of 55.76% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 605.22M for the trailing twelve months, which represents a growth of 20.54%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.22%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.47 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.50 points at the first support level, and at 17.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.73, and for the 2nd resistance point, it is at 20.20.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 1.46. In addition, the Quick Ratio stands at 1.42 and the Cash Ratio stands at 0.22. Considering the valuation of this stock, the price to sales ratio is 3.50, the price to book ratio is 5.80.
Transactions by insiders
Recent insider trading involved Weinberg Uri, Chief Innovation Officer, that happened on Mar 03 ’25 when 268.0 shares were sold. EVP, Pres., Novocure Oncology, Leonard Frank X completed a deal on Mar 03 ’25 to sell 2527.0 shares. Meanwhile, Chief Executive Officer Cordova Ashley sold 2053.0 shares on Mar 03 ’25.
